These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10975542)

  • 1. Neuroprotection and parkinsonism.
    Gundersen V; Dietrichs E
    Can J Neurol Sci; 2000 Aug; 27(3):261. PubMed ID: 10975542
    [No Abstract]   [Full Text] [Related]  

  • 2. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
    Linazasoro G; Sesar A; Valldeoriola F; Compta Y; Herrero MT; Martínez Castrillo JC; López Lozano JJ; Bergaretxe A; Vela L; Fernández JM; Castro A; Kulisevski J; Lezcano E; Vaamonde J; López Del Val J; Chacón J; Vivancos F; Luquin R; Aguilar M; Burguera JA; Salvador C; Menéndez Guisasola L; Catalán MJ; Mir P; Campos V; Grandas F; Mínguez A; Balaguer E; Yáñez R; Leiva C; García Ruiz P; Cubo E
    Neurologia; 2009 Mar; 24(2):113-24. PubMed ID: 19322690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meeting the challenge of treating epilepsy.
    Chadwick D; Wolf P
    Epileptic Disord; 2003 May; 5 Suppl 1():S7-8. PubMed ID: 12915335
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuroprotection in Parkinson disease.
    Simpkins N; Jankovic J
    Arch Intern Med; 2003 Jul; 163(14):1650-4. PubMed ID: 12885679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why hasn't neuroprotection worked in Parkinson's disease?
    Kieburtz K; Ravina B
    Nat Clin Pract Neurol; 2007 May; 3(5):240-1. PubMed ID: 17479072
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter: Antiepileptogenic and neuroprotective effects of erythropoietin: recent data.
    Mikati MA; Mohler Cornett KM
    Epilepsia; 2009 Jun; 50(6):1654-5. PubMed ID: 19646143
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression.
    Youdim MB; Grünblatt E; Levites-Royak Y; Mandel S
    Adv Neurol; 2001; 86():115-24. PubMed ID: 11553968
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroprotection in epilepsy: the Holy Grail of antiepileptogenic therapy.
    Sankar R
    Epilepsy Behav; 2005 Dec; 7 Suppl 3():S1-2. PubMed ID: 16243002
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroprotection for Parkinson's disease: prospects and promises.
    Olanow CW; Schapira AH; Agid Y
    Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Gout and risk of Parkinson disease: a prospective study.
    Schlesinger I; Schlesinger N
    Neurology; 2008 Jul; 71(1):70; author reply 70. PubMed ID: 18598007
    [No Abstract]   [Full Text] [Related]  

  • 12. Preclinical versus clinical neuroprotection.
    Grünblatt E; Schlösser R; Gerlach M; Riederer P
    Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
    [No Abstract]   [Full Text] [Related]  

  • 13. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The renewing drug therapy of epilepsy].
    Keränen T; Kälviäinen R
    Duodecim; 1997; 113(18):1749-54. PubMed ID: 10892066
    [No Abstract]   [Full Text] [Related]  

  • 15. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotection and neurodegenerative disease.
    Vajda FJ
    J Clin Neurosci; 2002 Jan; 9(1):4-8. PubMed ID: 11749009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S149-57; discussion S157-9. PubMed ID: 12666106
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatments in the early stage of Parkinson disease].
    Rascol O
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F77-84. PubMed ID: 18680822
    [No Abstract]   [Full Text] [Related]  

  • 19. I can't get no satisfaction: still no neuroprotection for Parkinson disease.
    Ahlskog JE
    Neurology; 2007 Oct; 69(15):1476-7. PubMed ID: 17923609
    [No Abstract]   [Full Text] [Related]  

  • 20. Practical importance of neuroprotection in Parkinson's disease.
    Riederer P; Gille G; Müller T; Przuntek H; Reichmann H; Riess O; Schwartz A; Schwarz J; Vogt T
    J Neurol; 2002 Oct; 249 Suppl 3():III/53-6. PubMed ID: 12522574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.